Orticumab (Anti-oxLDL) | LDL antibody | Read Reviews & Product Use Citations

Orticumab (MLDL1278A) is an antibody targeting oxidized or malondialdehyde-modified lipoprotein (LDL) that specifically inhibits oxidised low-density lipoproteins (oxLDL). Orticumab is involved in the modulation of autoimmune responses against oxLDL and improves atherosclerosis in an animal model. MW: 145.5 kD.

Purity & Quality Control

≥99

Choose Selective LDL Inhibitors

Biological Activity

Description	Orticumab (MLDL1278A) is an antibody targeting oxidized or malondialdehyde-modified lipoprotein (LDL) that specifically inhibits oxidised low-density lipoproteins (oxLDL). Orticumab is involved in the modulation of autoimmune responses against oxLDL and improves atherosclerosis in an animal model. MW: 145.5 kD.

Product Details

CAS No.	1314241-10-5
Molecular Weight	145.5 kDa
Isotype	Human IgG1
Source	CHO
Purification	AKTA
Sterility	0.2 μM filtered
Formulation	100mMPro-Ac,20mMArg-Ac，pH5.0
Storage (From the date of receipt)	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field